After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven was forced to rethink its strategy—cutting R&D...
Biohaven cut R&D by about 60% and pivoted toward obesity after the FDA rejected its spinocerebellar ataxia therapy.
Why it mattersFDA rejection and 60% R&D cuts force investors to reassess Biohaven's pipeline risk and capital allocation.